[go: up one dir, main page]

MA26641A1 - Utilisation de conjuges pef-ifn- & en association avec la ribavirine pour la fabrication de medicaments - Google Patents

Utilisation de conjuges pef-ifn- & en association avec la ribavirine pour la fabrication de medicaments

Info

Publication number
MA26641A1
MA26641A1 MA25613A MA25613A MA26641A1 MA 26641 A1 MA26641 A1 MA 26641A1 MA 25613 A MA25613 A MA 25613A MA 25613 A MA25613 A MA 25613A MA 26641 A1 MA26641 A1 MA 26641A1
Authority
MA
Morocco
Prior art keywords
pef
ribavirin
ifn
conjugates
drugs
Prior art date
Application number
MA25613A
Other languages
English (en)
Inventor
Zahm Freiderike
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26641(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26641A1 publication Critical patent/MA26641A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA25613A 1998-06-08 1999-06-08 Utilisation de conjuges pef-ifn- & en association avec la ribavirine pour la fabrication de medicaments MA26641A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98110433 1998-06-08

Publications (1)

Publication Number Publication Date
MA26641A1 true MA26641A1 (fr) 2004-12-20

Family

ID=8232086

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25613A MA26641A1 (fr) 1998-06-08 1999-06-08 Utilisation de conjuges pef-ifn- & en association avec la ribavirine pour la fabrication de medicaments

Country Status (34)

Country Link
US (3) US20030053986A1 (fr)
EP (1) EP1087778B1 (fr)
JP (2) JP3839667B2 (fr)
KR (2) KR20050055053A (fr)
CN (1) CN1170543C (fr)
AR (1) AR019855A1 (fr)
AT (1) ATE307597T1 (fr)
AU (1) AU767131B2 (fr)
BR (1) BR9911076A (fr)
CA (1) CA2334267C (fr)
CL (1) CL2010000828A1 (fr)
CO (1) CO5050297A1 (fr)
CZ (1) CZ298681B6 (fr)
DE (1) DE69927971T2 (fr)
DK (1) DK1087778T3 (fr)
ES (1) ES2251196T3 (fr)
HR (1) HRP20000808A2 (fr)
HU (1) HU228218B1 (fr)
ID (1) ID29285A (fr)
IL (2) IL139786A0 (fr)
MA (1) MA26641A1 (fr)
MY (1) MY124091A (fr)
NO (1) NO325598B1 (fr)
NZ (1) NZ508249A (fr)
PE (1) PE20000560A1 (fr)
PL (1) PL192364B1 (fr)
RS (1) RS50144B (fr)
RU (1) RU2271217C2 (fr)
SA (1) SA99200208B1 (fr)
SI (1) SI1087778T1 (fr)
TR (1) TR200003635T2 (fr)
TW (1) TWI241913B (fr)
WO (1) WO1999064016A1 (fr)
ZA (1) ZA200006814B (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50144B (sr) * 1998-06-08 2009-03-25 F. Hoffmann-La Roche Ag., Primena peg-inf-alfa 2a i ribavirina za proizvodnju leka za lečenje hroničnog hepatitisa c
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
KR100851861B1 (ko) * 2000-08-07 2008-08-13 사이클론 파아머슈티컬 인코오퍼레이티드 티모신, 인터페론 및 리바비린을 사용한 씨 형 간염의치료
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US7138376B2 (en) 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
KR100480429B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
MY140819A (en) 2002-06-28 2010-01-29 Idenix Caymans Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7824851B2 (en) * 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
KR20050109918A (ko) 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드의 제조 방법
NZ540913A (en) * 2002-12-23 2008-02-29 Idenix Cayman Ltd Process for the production of 3'-nucleoside prodrugs
CA2734052A1 (fr) 2003-05-30 2005-01-13 Pharmasset, Inc. Analogues de nucleosides fluores modifies
BRPI0512360A (pt) * 2004-06-23 2008-03-11 Idenix Cayman Ltd derivados de 5-aza-7-deazapurina para o tratamento de flaviviridae
US8886272B2 (en) 2004-07-13 2014-11-11 Dexcom, Inc. Analyte sensor
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
BRPI0515279A (pt) 2004-09-14 2008-07-15 Pharmasset Inc preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados
EP2899277A1 (fr) 2004-11-26 2015-07-29 Pieris AG Composé à affinité pour l'antigène associé aux lymphocytes T cytotoxiques (CTLA-4)
BRPI0614863A2 (pt) * 2005-08-15 2011-04-19 Hoffmann La Roche uso de conjugados de peg-ifn-alfa em associação a ribavirina, bem como kit compreendendo os mesmos
US9201979B2 (en) * 2005-09-14 2015-12-01 Millennial Media, Inc. Syndication of a behavioral profile associated with an availability condition using a monetization platform
WO2007075876A2 (fr) * 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Procede pour la preparation d’un intermediaire synthetique pour la preparation de nucleosides ramifies
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
JP5711118B2 (ja) 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
AU2009293493B2 (en) * 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2010075554A1 (fr) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthèse de nucléosides de type purine
EP2376514A2 (fr) 2008-12-23 2011-10-19 Pharmasset, Inc. Analogues de nucléoside
CN102458470B (zh) 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
CN102612362A (zh) 2009-08-05 2012-07-25 皮里斯股份公司 脂质运载蛋白突变蛋白的控制释放制剂
CA2779244A1 (fr) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Regimes posologiques pour une therapie en combinaison contre le vhc comprenant bi201335, l'interferon alpha et la ribavirine
EP2510357B1 (fr) 2009-12-07 2016-03-30 Pieris AG Mutéines de la lipocaline 2 humaine (lcn2, hngal) ayant une affinité pour une cible donnée
RS54368B1 (sr) 2010-03-31 2016-04-28 Gilead Pharmasset Llc Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
RS58839B1 (sr) 2010-06-08 2019-07-31 Pieris Pharmaceuticals Gmbh Muteini lipokalina u suzama koji vezuju il-4 r alfa
US9051382B2 (en) 2010-08-16 2015-06-09 Pieris Ag Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins that bind hepcidin and nucleic acid encoding such
CA2817779C (fr) 2010-11-15 2019-02-19 Pieris Ag Muteines de lipocaline humaine 2 ayant de l'affinite pour le glypicane-3 (gpc3)
CA2818853A1 (fr) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides destines a la therapie contre le virus de l'hepatite c et le virus de la dengue
EP2646552B1 (fr) 2010-12-02 2017-07-05 Pieris Pharmaceuticals GmbH Mutéines dérivées de la lipocaline 2 humaine à affinité pour ctla-4
UA116087C2 (uk) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Композиція для лікування вірусу гепатиту c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN103998053B9 (zh) 2011-12-13 2020-07-21 皮里斯制药有限公司 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
US20140039923A1 (en) * 2012-08-03 2014-02-06 AxelaCare Health Solutions, Inc. Computer program, method, and system for receiving and managing patient data gathered during patient treatments
WO2014076321A1 (fr) 2012-11-19 2014-05-22 Pieris Ag Nouveaux polypeptides de liaison spécifique et leurs utilisations
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CN105246503A (zh) 2013-03-14 2016-01-13 第一三共株式会社 Pcsk9的新颖结合蛋白
SG11201600919UA (en) 2013-08-27 2016-03-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2015104406A2 (fr) 2014-01-13 2015-07-16 Pieris Ag Polypeptide multi-spécifique utilisé pour l'immunomodulation tumorale localisée
CN106573964B (zh) 2014-05-22 2021-07-16 皮里斯制药有限公司 新型特异性结合多肽及其用途
KR20170105609A (ko) 2015-01-28 2017-09-19 피어이스 파마슈티컬즈 게엠베하 신생혈관형성에 특이적인 신규한 단백질
EA035824B1 (ru) 2015-02-18 2020-08-17 Пайерис Фармасьютикалс Гмбх Новые белки, специфичные к пиовердину и пиохелину
JP6783797B2 (ja) 2015-05-04 2020-11-11 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん融合ポリペプチド
EP3292137B1 (fr) 2015-05-04 2022-09-07 Pieris Pharmaceuticals GmbH Protéines spécifiques pour cd137
SMT202300026T1 (it) 2015-05-18 2023-03-17 Pieris Pharmaceuticals Gmbh Polipeptide di fusione anti-cancro
CA2982034A1 (fr) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Muteines de la lipocaline 2 humaine avec affinite pour glypican-3 (gpc3)
EP3115371A1 (fr) 2015-07-07 2017-01-11 Sanofi Molécules de fusion
EP3322433B1 (fr) 2015-07-15 2023-05-31 Pieris Pharmaceuticals GmbH Nouvelles protéines spécifiques à lag-3
CN108699162A (zh) 2015-11-30 2018-10-23 皮里斯澳大利亚有限公司 新型抗血管生成融合多肽
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (fr) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Protéines spécifiques de cd137
CN110402252A (zh) 2017-01-18 2019-11-01 皮里斯制药有限公司 对lag-3具有结合亲和力的脂质运载蛋白突变蛋白
MX2021000401A (es) 2018-07-31 2021-03-25 Pieris Pharmaceuticals Gmbh Nuevas proteinas de fusion especificas para cd137 y pd-l1.
MX2021010039A (es) 2019-02-26 2021-09-21 Pieris Pharmaceuticals Gmbh Novedosas proteinas de fusion especificas para cd137 y gpc3.
KR20230020443A (ko) 2020-06-05 2023-02-10 피어이스 파마슈티컬즈 게엠베하 4-1bb 표적화 다량체 면역조절제
KR20230165917A (ko) 2021-04-08 2023-12-05 피어이스 파마슈티컬즈 게엠베하 결합 조직 성장 인자(ctgf)에 특이적인 신규 리포칼린 뮤테인
WO2022243341A1 (fr) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Mutéines de lipocaline ayant une affinité de liaison pour ox40
IL319272A (en) 2022-09-21 2025-04-01 Seagen Inc ROVEL FUSION protein specific for CD137 and CD228
WO2025175123A1 (fr) 2024-02-16 2025-08-21 Seagen Inc. Méthodes de traitement du cancer à l'aide de protéines de fusion spécifiques pour cd137 et cd228

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681848A (en) * 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3719046A1 (de) * 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5238915A (en) * 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
NZ276943A (en) * 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
DE69632062T2 (de) * 1995-11-02 2004-11-18 Schering Corp. Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
RS50144B (sr) * 1998-06-08 2009-03-25 F. Hoffmann-La Roche Ag., Primena peg-inf-alfa 2a i ribavirina za proizvodnju leka za lečenje hroničnog hepatitisa c

Also Published As

Publication number Publication date
PL344794A1 (en) 2001-11-19
TWI241913B (en) 2005-10-21
US20050031589A1 (en) 2005-02-10
ID29285A (id) 2001-08-16
CZ298681B6 (cs) 2007-12-19
DE69927971D1 (de) 2005-12-01
ATE307597T1 (de) 2005-11-15
RS50144B (sr) 2009-03-25
ES2251196T3 (es) 2006-04-16
HK1037981A1 (en) 2002-03-01
CN1170543C (zh) 2004-10-13
AU4503399A (en) 1999-12-30
KR20010052622A (ko) 2001-06-25
CA2334267A1 (fr) 1999-12-16
IL139786A (en) 2007-10-31
DE69927971T2 (de) 2006-07-27
SI1087778T1 (sl) 2006-02-28
TR200003635T2 (tr) 2001-04-20
EP1087778A1 (fr) 2001-04-04
EP1087778B1 (fr) 2005-10-26
AR019855A1 (es) 2002-03-20
DK1087778T3 (da) 2005-12-19
CN1305382A (zh) 2001-07-25
ZA200006814B (en) 2002-05-03
HU228218B1 (en) 2013-02-28
NZ508249A (en) 2003-02-28
JP2002517451A (ja) 2002-06-18
US20030053986A1 (en) 2003-03-20
NO20006178D0 (no) 2000-12-05
CZ20004487A3 (en) 2001-06-13
KR20050055053A (ko) 2005-06-10
SA99200208B1 (ar) 2006-08-15
WO1999064016A1 (fr) 1999-12-16
PL192364B1 (pl) 2006-10-31
BR9911076A (pt) 2001-02-20
MY124091A (en) 2006-06-30
JP2006160759A (ja) 2006-06-22
JP3839667B2 (ja) 2006-11-01
CA2334267C (fr) 2009-02-17
HUP0102033A3 (en) 2010-01-28
HRP20000808A2 (en) 2001-10-31
US20070196385A1 (en) 2007-08-23
CL2010000828A1 (es) 2011-02-11
CO5050297A1 (es) 2001-06-27
NO20006178L (no) 2000-12-05
RU2271217C2 (ru) 2006-03-10
AU767131B2 (en) 2003-10-30
YU77000A (sh) 2003-08-29
HUP0102033A2 (hu) 2001-10-28
NO325598B1 (no) 2008-06-23
IL139786A0 (en) 2002-02-10
PE20000560A1 (es) 2000-07-05

Similar Documents

Publication Publication Date Title
MA26641A1 (fr) Utilisation de conjuges pef-ifn- & en association avec la ribavirine pour la fabrication de medicaments
IL202633A0 (en) Sulfonamide derivatives and pharmaceutical compositions containing the same
DE60019578D1 (de) Polyolefin und die herstellung davon
NO20005913L (no) Legemiddelsammensetning
NO20004617L (no) Tablett som disintegrerer hurtig i munnhulen
DE69908021D1 (de) Ziprasidonhaltige Arzneimittel
DE59912838D1 (de) Pharmazeutisches faktor vii-präparat
IL138725A0 (en) Sulfonamide derivatives and pharmaceutical compositions containing the same
HUP0102585A3 (en) Thienylazolylalcoxyethanamin derivatives preparation the same and their use as medicaments
DE50001455D1 (de) Blisterverpackung
DE59900520D1 (de) Diaminobenzol-Derivate enthaltende Färbemittel sowie die Diaminobenzol-Derivate
DK1466615T3 (da) Farmaceutisk præparat
NO20006025L (no) Hydrokolloid-sötvareprodukt
PT1210085E (pt) Solucoes farmaceuticas de levosimendano
ID30032A (id) Formulasi farmasi
IL143439A0 (en) Sulfonamide derivatives and pharmaceutical compositions containing the same
EP1153612A4 (fr) Potentialisateurs d'agent anticancereux
EP1363637A4 (fr) Composes pyrimidiques et technique de preparation et d'utilisation de ces composes
EE200100697A (et) Farmatseutiline kompleks
EP1124557A4 (fr) Composition pharmaceutique
EP1053358A4 (fr) Utilisation de l'integrase du vih-1 dans le criblage de medicaments candidats diriges contre le vih-1
MA26677A1 (fr) Medicaments antiparkinsoniens.
DE59905747D1 (de) Blisterpackung
FR2794001B1 (fr) La cravate suspensoir
BR7902842Y1 (pt) disposiÇço introduzida em quadro de distribuiÇço.